Prosecution Insights
Last updated: April 19, 2026

Examiner: JACKSON, SHAWQUIA

Tech Center 1600 • Art Units: 1626

This examiner grants 78% of resolved cases

Performance Statistics

77.9%
Allow Rate
+17.9% vs TC avg
1839
Total Applications
-3.4%
Interview Lift
902
Avg Prosecution Days
Based on 1810 resolved cases, 2023–2026

Rejection Statute Breakdown

2.0%
§101 Eligibility
19.3%
§102 Novelty
7.1%
§103 Obviousness
52.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18545029 DRUG FORMULATIONS OF (R)-1-(1-ACRYLOYLPIPERIDIN-3-YL)-4-AMINO-3-(4-PHENOXYPHENYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONE Non-Final OA Genzyme Corporation
18545711 PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS Non-Final OA Hoffmann-La Roche Inc.
18558908 INHIBITORS OF SARS-COV-2 Non-Final OA The Texas A&M University System
18406841 Method for Treating Diseases Using SMARCA2/4 Degraders Non-Final OA Aurigene Oncology Limited
18470548 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Non-Final OA AstraZeneca AB
17751474 PROTECTED TRIAZABUTADIENE COMPOSITIONS FOR CELLULAR STUDIES IN INTACT BIOLOGICAL SYSTEMS Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
18797055 PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES Final Rejection ZYDUS LIFESCIENCES LIMITED
17821952 SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAs) AND METHODS OF USE THEREOF Non-Final OA University of Tennessee Research Foundation
17921260 A FUNGICIDAL COMPOUND AND PROCESS OF PREPARATION THEREOF Non-Final OA UPL Limited
18577481 MODULATORS OF PROTEIN KINASES Non-Final OA VIBLIOME THERAPEUTICS, LLC
18466489 PROCESS FOR PREPARATION OF IPCONAZOLE & ITS INTERMEDIATES Non-Final OA UPL Europe LTD
18565565 FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME Non-Final OA Compass Pathfinder Ltd.
18239315 Composition for preventing or treating cachexia and muscle loss Non-Final OA METAFINES.CO.LTD.
18276709 PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF Non-Final OA Eleusis Therapeutics US, Inc.
18276588 ANTIBACTERIAL COMPOUNDS Non-Final OA Blacksmith Medicines, Inc.
18258666 METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR Non-Final OA Inner Mongolia University of Technology
18036269 NOVEL CYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THE USE OF SAID CYCLIC COMPOUNDS IN COSMETIC PREPARATIONS Non-Final OA EBERHARD KARLS UNIVERSITAET TUEBINGEN
18017038 CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE Non-Final OA Romark Laboratories, L.C.
17651439 OXADIAZOLES FOR USE IN CONTROLLING PHYTOPATHOGENIC FUNGI Non-Final OA PI INDUSTRIES LTD.
18015561 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE Final Rejection BEIGENE, LTD.
18012985 COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE Final Rejection CRESCENTA BIOSCIENCES
18011408 AMIDO COMPOUNDS Non-Final OA Anaxis Pharma Pty Ltd

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month